Save
Serum neurofilament light chain and glial fibrillary acid protein analysis in patients with multiple sclerosis: a clue to distinguish inflammation and neurodegeneration?
Author(s): ,
X. Ayrignac
Affiliations:
Hopital Gui de Chauliac | Neurology, Montpellier University Hospital
,
A. Maleska-Maceski
Affiliations:
Laboratoire de Biochimie-Protéomique Clinique - IRMB - CRB - Inserm U 11183, CHU Montpellier, Hîpital St-Eloi - Université Montpellier, Montpellier
,
C. Carra-Dalliere
Affiliations:
Hopital Gui de Chauliac | Neurology, Montpellier University Hospital, Montpellier Cedex
,
M. Charif
Affiliations:
Hopital Gui de Chauliac | Neurology, Montpellier University Hospital, Montpellier Cedex
,
C. Catteau
Affiliations:
Laboratoire de Biochimie-Protéomique Clinique - IRMB - CRB - Inserm U 11183, CHU Montpellier, Hôpital St-Eloi - Université Montpellier, Montpellier, France
,
N. Ginestet
Affiliations:
Laboratoire de Biochimie-Protéomique Clinique - IRMB - CRB - Inserm U 11183, CHU Montpellier, Hôpital St-Eloi - Université Montpellier, Montpellier, France
,
P. Prin
Affiliations:
Hopital Gui de Chauliac | Neurology, Montpellier University Hospital, Montpellier Cedex
,
L. Corti
Affiliations:
Hopital Gui de Chauliac | Neurology, Montpellier University Hospital, Montpellier Cedex
,
F. Pinna
Affiliations:
Hopital Gui de Chauliac | Neurology, Montpellier University Hospital, Montpellier Cedex
,
S. Lehmann
Affiliations:
Laboratoire de Biochimie-Protéomique Clinique - IRMB - CRB - Inserm U 11183, CHU Montpellier, Hôpital St-Eloi - Université Montpellier, Montpellier, France
P. Labauge
Affiliations:
Hopital Gui de Chauliac | Neurology, Montpellier University Hospital, Montpellier Cedex
ECTRIMS Online Library. ayrignac x. Oct 12, 2018; 228137; P1759
xavier ayrignac
xavier ayrignac
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: P1759

Type: Poster Sessions

Abstract Category: N/A

Background: Serum neurofilament light chain (s-NFL), a marker of neuronal injury is considered as a promising prognostic biomarker in multiple sclerosis (MS). S-NFL is correlated with acute inflammation and neurodegenerative process. Additional biomarkers are needed to distinguish patients at risk from relapse and patients at risk from progression.
Objectives: To investigate s-NFL and serum glial fibrillary acid protein (s-GFAP) in a MS patients cohort.
Methods: We assessed s-NFL and s-GFAP (Neurology 4-plex A Simoa kit, Quanterix, USA) in 129 MS patients (106 females) including 18 PPMS and 111 RRMS (22 with recent relapse). Fifty four of these RRMS patients were treated at the time of blood sample.
Results: Mean age at blood sample was respectively 52, 41 and 36 years in PPMS, RRMS without relapse and RRMS with recent relapse and mean disease duration was 4, 8 and 1.3 years. Both s-NFL (9.56±5 vs 13.6±6.6 pg/ml) and s-GFAP (82.3±38 vs 130.3±73 pg/ml) were significantly lower in RRMS than in PPMS patients (respectively p=0.02 and 0.01). In RRMS patients, although it was not significant, s-NFL (10.2 vs 9.4pg/ml) was higher and s-GFAP (72.5 vs 84.7 pg/ml) was lower in patients with recent relapse. S-NFL level (8.9 vs 10.2 pg/ml) tended to be lower in treated versus non-treated patients, s-GFAP levels were not different. In treated RRMS patients, although we only included a small number of patients for each molecule, s-NFL level was lower in patients treated with natalizumab and s-GFAP level was lower in patients treated with dimethyl fumarate.
Conclusion: Our data confirm that s-NFL are higher in PPMS patients and, albeit non-significantly in patients with recent relapse. Moreover, s-GFAP level is significantly elevated in PPMS patients compared to RRMS. In treated RRMS patients, S-NFL and s-GFAP levels seem to vary depending on the type of disease modifying therapy and suggest distinct impact on astrocytic and neuronal damage.
Disclosure: Xavier Ayrignac has received consulting and lecturing fees, travel grants and research support from Bayer-Schering, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, and Teva Pharma.
Aleksandra Maleska-Maceski nothing to disclose
Clarisse Carra Dalliere nothing to disclose
Mahmoud Charif nothing to disclose
Cindy Catteau nothing to disclose
Nelly Ginestet nothing to disclose
Pauline Prin nothing to disclose
Frédéric Pinna nothing to disclose
Frederic Pinna nothing to disclose
Sylvain Lehman nnothing to disclose
Pierre Labauge nothing to disclose

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings